Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab

Sponsor
West Penn Allegheny Health System
Study ID
NCT01331616
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab (Avastin) — DRUG
    Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.

Study Details

Does treatment with bevacizumab (Avastin) in combination with prior or current radiotherapy lead to optic neuropathy?

Key Dates

First listed
Apr 8, 2011
Start date
Mar 31, 2011
Status verified
Nov 2021
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab (Avastin)

Primary Outcome Measure

Measurement of Visual Evoked Potentials (optic nerve function and visual processing) and optic nerve function in 10 patients. [ Time Frame: 1 year ]

Related Studies